Panacea Biotec Limited ( Panacea Biotec ) has scheduled its 42nd Annual General Meeting (AGM) for Tuesday, September 29, 2026, at 11:30 am. The meeting will be held exclusively through Video Conferencing or Other Audio-Visual Means (VC/OAVM), adhering to the provisions of the Companies Act, 2013, and circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India.

The deemed venue for the AGM is the company’s registered office located on the Ambala-Chandigarh Highway in Lalru, Punjab. Shareholders will have the opportunity to transact the business items outlined in the AGM notice, which includes the adoption of audited financial statements for the financial year 2025-26.

E-voting and Participation Details

Members holding shares in demat or physical form can cast their votes electronically through remote e-voting or during the AGM via the VC/OAVM facility. The company has engaged Skyline Financial Services Pvt. Ltd. as its Registrar and Share Transfer Agent (RTA) to facilitate these processes.

Key logistical details for shareholders include:

• Notice Dispatch: The AGM notice and Annual Report for FY25-26 will be sent electronically only to members who have registered their email addresses with the company, RTA, or Depository Participants (DPs).
• Physical Shareholders: Members holding shares in physical form without registered emails are requested to update their details at the RTA’s portal to receive the notice and voting credentials.
• Demat Shareholders: Those holding shares in demat form should contact their respective DPs to ensure their contact information is up to date.

The remote e-voting window and specific login instructions will be detailed in the formal notice of the AGM. Members who vote remotely prior to the meeting may attend the virtual session but cannot vote again. Conversely, those who do not vote remotely can cast their votes during the live AGM session.

Regulatory Compliance

This announcement aligns with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The public notice regarding the AGM was published in Business Standard (all editions) and Desh Sewak (Punjabi) on August 18, 2026, ensuring broad dissemination among stakeholders.

Panacea Biotec reported a decline in profitability for the first quarter despite growth in top-line revenue. The company’s consolidated net profit fell to ₹23 million, compared to ₹41 million in the corresponding period of the previous fiscal year.

Revenue for the quarter rose to ₹2 billion, up from ₹1.7 billion year-on-year. The divergence between revenue growth and profit contraction indicates pressure on margins during the period.

Financial Highlights

What the Numbers Show

While revenue expanded by approximately 17.6% (derived from ₹1.7B to ₹2B), net profit declined by roughly 43.9% (from ₹41M to ₹23M). This inverse movement suggests that cost structures or other expenses grew at a faster rate than revenue, eroding the bottom line despite higher sales.